ASSOCIATION OF ENDOMETRIOSIS WITH CARDIOVASCULAR EVENTS THE ROLE OF SYSTEMIC INFLAMMATION AND GONADOTROPIN RELEASING HORMONETHERAPY

Authors

  • Rimma Gagikovna Antonyan Saratov State Medical University named after V. I. Razumovsky, BolshayaKazachiast., 112 Saratov, 410012 Russia, ORCID: https://orcid.org/0009-0004-6151-7625 Author
  • Elena Maksimovna Klekovkina Saratov State Medical University named after V. I. Razumovsky, BolshayaKazachiast., 112 Saratov, 410012 Russia, ORCID: https://orcid.org/0009-0001-3098-4800 Author
  • Anastasia Sergeevna Moskovskaya The Chuvash state university named after I. N. Ulyanov», Cheboksary, Russia, 15 Moskovsky Prospekt, 428014, ORCID: https://orcid.org/0009-0000-9927-7760 Author
  • Maria Dmitrievna Arkhipova South Ural State Medical University, Vorovskogo St., 64, Chelyabinsk, Chelyabinsk region, 454092, ORCID: https://orcid.org/0009-0008-1603-9141 Author
  • Vera Mikhailovna Cherkina National Research Moscow State University of Civil Engineering,129337, 26, Yaroslavskoye Shosse, Moscow, Russia Author
  • Ivan Alekseevich Barannikov Federal State Budgetary Educational Institution of Higher Education «Astrakhan State Medical University" Medical Faculty, 414000, Astrakhan, Bakinskaya str. 121, ORCID: https://orcid.org/0000-0002-8100-9992 Author
  • Ziyarat Salimsoltanovna Isaeva Astrakhan State Medical University ,121, Bakinskaya Street, Astrakhan, Russia, 414000, https://orcid.org/0009-0001-0962-3349 Author

DOI:

https://doi.org/10.4238/4ngd0539

Abstract

The aim of the study was to evaluate the association of endometriosis in women of reproductive age with cardiovascular events, as well as to analyze the role of systemic inflammation and gonadotropin-releasing hormone (GnRH) agonist therapy.A single-center observational study was conducted that included 110 patients with laparoscopically confirmed endometriosis who were treated in a Novosibirsk hospital. Clinical and demographic characteristics, traditional cardiovascular risk factors, history of cardiovascular events, levels of highly sensitive C-reactive protein (hs-CRP), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), as well as the presence and duration of GnRHagonist therapy were evaluated. The primary endpoint was a combined indicator, including myocardial infarction, ischemic stroke, transient ischemic attacks, episodes of unstable angina and hospitalization for hypertension decompensation. Cardiovascular events were reported in some patients and were associated with an older age, an increased body mass index, a higher incidence of hypertension, and more pronounced systemic inflammation in terms of hs-CRP, IL-6, and TNF-α levels. GnRH agonist therapy, especially with a duration of ≥ 6 months, was associated with an increased incidence of cardiovascular events. In a multivariate logistic regression, increased hs-CRP and long-term GnRHagonist therapy maintained an independent association with cardiovascular events after adjusting for age, body mass index, and hypertension. The results obtained emphasize the importance of endometriosis as a condition associated with increased cardiovascular risk, and indicate the important role of systemic inflammation and hormone therapy in the formation of an unfavorable cardiovascular profile in women of reproductive age. A comprehensive interdisciplinary approach involving a gynecologist and a cardiologist, early risk stratification and individualization of therapy are needed.

Downloads

Published

2026-03-20

Issue

Section

Articles

How to Cite

ASSOCIATION OF ENDOMETRIOSIS WITH CARDIOVASCULAR EVENTS THE ROLE OF SYSTEMIC INFLAMMATION AND GONADOTROPIN RELEASING HORMONETHERAPY. (2026). Genetics and Molecular Research. https://doi.org/10.4238/4ngd0539